First Implantation of Endovastec Minos Stent Graft System Completed in Brazil

São Paulo, Brazil, 17 June 2021 — Minos® Abdominal Aortic Stent-Graft and Delivery System (Minos® Stent Graft System), a product developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), was recently used in Brazil for the first time. This marks the System’s tenth overseas market entry, following its approval in Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia and Hungary.

The procedure, led by Dr. Victor Maia and Dr. Guilherme Meirelles of the Samaritano Paulista Hospital, involved a patient admitted to hospital with sudden onset of pain. The patient was shown to have a challenging abdominal aortic aneurysm over 5 cm in diameter, involving the superior mesenteric artery with a very tortuous iliac artery hindering access. The surgical team selected the Minos® Stent Graft System for placement across the superior mesenteric artery and used the chimney technique to reconstruct the superior mesenteric artery and the left and right renal arteries. Postoperative angiography showed an effectively isolated aneurysm, and the stent graft was well conformed to the patient’s anatomy, allowing for the restoration of blood flow in the branch stent, indicating a successful operation.

A member of the surgical team commented, “It is the outstanding performance of Minos® that made the procedure a success. The ultra-low profile delivery sheath of Minos® was able to conform to the patient’s tortuous iliac artery. In addition, the system provided a very smooth control experience throughout the procedure.”

Zhenghua Miao, President of Endovastec™, said, “Since it entered overseas markets, the Minos® Stent Graft System has shown excellent performance in clinical practice in a number of countries in Europe and South America. It is receiving recognition by experts for providing a better solution for patients with complex abdominal aortic anatomical patterns. As we continue to make our products available in new markets, Endovastec™ will further enhance in-depth cooperation with overseas clinical experts, striving to promote more high-quality and innovative solutions for the treatment of aortic and peripheral vascular diseases in overseas markets, so as to benefit more patients worldwide. ”

The Minos® Stent Graft System features a three-piece design that enables a flexible assembly to accommodate different size requirements. The advanced core technologies are able to meet the treatment needs of a wider range of abdominal aortic aneurysms with complex anatomy, which reduces the rate of complications such as device migration, endoleaks or occlusion, and thus lower the risk of long-term reintervention.

About Endovastec™

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), which is a subsidiary of MicroPort Scientific Corporation (MicroPort®, 00853.HK), was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New “Little Giant” Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.